Compare Invesco DB Commodity Index Tracking Fund (DBC) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Commodity Index Tracking Fund vs Enveric Biosciences Inc — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $32.96 (market cap $1.92B), while Enveric Biosciences Inc trades at $1.45 (market cap $6.80M). The key difference: Invesco DB Commodity Index Tracking Fund is far larger — about 282.4× Enveric Biosciences Inc's market cap, and Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Commodity Index Tracking Fund for 60 Days and Enveric Biosciences Inc for 14 Days on average.
| DBC | ENVB | |
|---|---|---|
Market Cap | $1.92B | $6.80M |
Volume | 1,375,556 | 64,867 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $33.68 | $10.80 |
52-Week Low | $22.07 | $1.27 |
Typical Hold Time | 60 Days | 14 Days |
Enterprise Value | — | -$1.49M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBC trades at $32.91, up 1.23% with a bullish technical signal from moving averages. The company reported $82.59M revenue and $22.38M net income for 2024, showing improved profitability with a 27.1% margin. Strong cash flow from operations of $431.54M supports a healthy balance sheet with minimal debt and $1.28B shareholder equity. Recent news highlights commodity ETF strategies amid dollar weakness.
The outlook appears positive with technical momentum and fundamental improvement, though revenue volatility remains a concern. Investment opportunity lies in the debt-free balance sheet and cash generation, while risks include inconsistent revenue trends and commodity market exposure.
ENVB trades at $1.52, up 1.67% with a bearish technical outlook despite recent earnings beats. The company shows no revenue but has improved quarterly EPS performance, with Q4 2025 turning positive. Analyst sentiment is bullish with 75% buy ratings, while technical indicators show selling pressure with 15 sell signals versus 1 buy.
Investment outlook remains speculative given negative profitability metrics and zero revenue, though patent developments and FDA guidance provide potential catalysts. Key risks include cash burn and clinical trial outcomes, while institutional support through financing offers near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
